quinazolines has been researched along with Carcinoma in 140 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (2.86) | 18.7374 |
| 1990's | 7 (5.00) | 18.2507 |
| 2000's | 51 (36.43) | 29.6817 |
| 2010's | 75 (53.57) | 24.3611 |
| 2020's | 3 (2.14) | 2.80 |
| Authors | Studies |
|---|---|
| Fang, H; He, H; Li, Y; Liu, Y; Xu, J; Zhang, S; Zhang, Y | 1 |
| Chen, X; Fang, H; He, H; Li, Y; Liu, Y; Xu, J; Zhang, S; Zhang, Y | 1 |
| Cai, G; Gong, Q; Liang, X; Liu, J; Song, C; Wang, R; Wang, X | 1 |
| Chin, CC; Huang, YC; Kuo, YH; Lee, YR; Li, JM; Shi, CS | 1 |
| Cohen, PR; Udkoff, J | 1 |
| Cai, G; Cai, S; Chen, Y; Li, Y; Liang, X; Liu, J; Meng, X; Qi, Y; Qiu, C; Xu, Y; Zheng, H | 1 |
| Liu, F; Liu, Y; Luo, H; Wu, Y; Zhao, Y | 1 |
| Hou, S; Li, Y; Liu, Q; Liu, Y; Qi, M; Shao, L; Zhang, J | 1 |
| Lu, H; Xie, Z; Xu, Y | 1 |
| Abelleira, E; Bueno, F; Jerkovich, F; Pitoia, F; Schmidt, A | 1 |
| Choi, MG; Ihm, SH; Kang, JG; Kim, CS; Kim, SH; Lee, SJ | 1 |
| Deng, XB; Jin, ZR; Li, XQ; Liu, QZ; Liu, Y; Ma, L; Miao, XB; Sun, DX; Testa, JR; Wu, Y; Xiao, GH; Yao, KT; Zhang, G | 1 |
| Chan, KS; Lim, KH; Lim, WT; Lynette, O; Montoya, J; Ng, QS; Sakktee Krisna, S; Takano, A; Tan, DS; Tan, EH | 1 |
| Baudin, E; Bonichon, F; Borget, I; Brassard, M; Chougnet, CN; Claude-Desroches, M; de la Fouchardière, C; Do Cao, C; Giraudet, AL; Leboulleux, S; Massicotte, MH; Schlumberger, M | 1 |
| Chiou, SK; Ge, L; Hoa, N; Hodges, A; Jadus, MR | 1 |
| Muggia, F; Teplinsky, E | 1 |
| Lin, J; Wang, L; Xie, B; Xu, T; Zhang, W; Zheng, J; Zhou, J | 1 |
| Osborne, CK; Rimawi, MF; Schiff, R | 1 |
| Franckena, M; Kraan, J; Sleijfer, S; van Doorn, L; van Meerten, E; Westermann, A; Wiemer, E | 1 |
| Choi, HE; Choi, JH; Kim, JY; Lee, HH; Lee, KT; Lee, YS; Shin, DH; Shin, JS | 1 |
| Chow, JP; Hong, MJ; Li, J; Ma, HT; Mak, JP; Man, WY; Poon, RY | 1 |
| Boufraqech, M; Boxer, MB; Copland, JA; Davis, S; Kebebew, E; Kiefer, JA; Li, Z; Mehta, A; Shen, M; Smallridge, RC; Tian, Z; Wang, J; Yu, Z; Zhang, L; Zhang, Y | 1 |
| Althouse, SK; Burns, M; Gubens, MA; Loehrer, PJ; Pedro-Salcedo, MS; Perkins, SM; Wakelee, HA | 1 |
| Bertotti, A; Catalano, I; Leto, SM; Migliardi, G; Sassi, F; Throsby, M; Torri, V; Trusolino, L; Zanella, ER | 1 |
| Aasrum, M; Brusevold, IJ; Christoffersen, T; Sandnes, D; Tveteraas, IH; Ødegård, J | 1 |
| Anders, CK; Barry, WT; Berry, DA; Carey, LA; Cheang, MC; Cirrincione, CT; Harris, LN; Henry, NL; Hoadley, KA; Hudis, CA; Iglesia, M; Krop, IE; Ollila, DW; Perou, CM; Pitcher, BN; Singh, B; Weckstein, DJ; Winer, EP | 1 |
| Ai, P; Li, J; Peng, X; Wang, L; Zeng, Y; Zhang, Q | 1 |
| Cui, Y; Li, X; Liu, H; Wang, D; Xu, T; Yin, B; Zhang, C; Zhang, Y | 1 |
| Bell, D; Hanna, EY; Jiffar, TW; Kupferman, ME; Lee, J; Myers, JN; Pickering, C; Takahashi, Y | 1 |
| Fang, W; Tian, Y; Xue, C; Zhan, J; Zhang, J; Zhang, L; Zhao, Y | 1 |
| Chang, WC; Chu, YY; Hour, TC; Li, CF; Wang, JM; Wang, WJ; Wang, YH; Yen, CJ | 1 |
| Ichihara, E; Kiura, K; Kubo, T; Ohashi, K; Osawa, M; Takata, M; Takata, S; Takigawa, N; Tanimoto, M | 1 |
| Chen, N; Huang, P; Lin, Z; Liu, L; Peng, P; Tang, C; Wang, Z | 1 |
| Babur, M; Shannon, AM; Stratford, IJ; Telfer, BA; Wedge, SR; Williams, KJ | 1 |
| Brattain, MG; Hauser, J; Hu, YP; Humphrey, LE; Li, W; Panasiewicz, M; Patil, SB | 1 |
| Muslimov, GF | 1 |
| Altaha, R; Hogan, T; Williams, HJ | 1 |
| Coombes, RC; Francis, RE; Guest, SK; Krol, J; Kwok, JM; Lam, EW; McGovern, UB; Myatt, SS; Peck, B; Polychronis, A; Wang, J | 1 |
| French, JD; Grzywa, RL; Haugen, BR; Kerege, AA; Schweppe, RE; Sharma, V | 1 |
| Li, L; Li, XQ; Liu, H; Liu, XJ; Zhen, YS | 1 |
| Chen, AQ; Liu, B; Yang, ZG | 1 |
| Dieras, V; Florance, A; Gomez, HL; Johnston, S; Kennedy, MJ; Lichinitser, M; Maltzman, J; Manikhas, A; O'Rourke, L; Oliva, C; Pegram, M; Pippen, J; Pivot, X; Press, MF; Romieu, G; Sadeghi, S; Stein, S | 1 |
| Choi, YJ; Kim, CH; Lee, JC; Lee, JK; Lee, SS; Na, II; Rho, JK; Ryoo, BY; Yang, SH; Yoo, YD | 1 |
| Arbushites, M; Di Leo, A; Finn, RS; Gagnon, R; Koehler, M; Press, MF | 1 |
| Greco, FA; Hainsworth, JD; Lane, CM; Murphy, PB; Naot, Y; Spigel, DR; Thompson, DS; Waterhouse, DM | 1 |
| Bedard, PL; de Azambuja, E; Devriendt, D; Lossignol, D; Piccart-Gebhart, MJ; Tomasello, G | 1 |
| Iwakawa, J; Kawamata, Y; Kumamoto, T; Suetsugu, T; Tanoue, A | 1 |
| Bertram, JP; Lavik, EB; Reiter, JL; Robinson, R | 1 |
| Berlin, ST; Humphreys, BD; Ivy, P; Matulonis, UA; Penson, RT; Robinson, ES; Tyburski, K | 1 |
| Bean, P; Billig, J; Cases, S; Davis, J; Feiler, HS; Gray, JW; Kuo, WL; Martin, S; Purcell, JW; Reddy, M; Samayoa, K; Thomsen, K; Vo, H; Wood, KW; Ziyad, S | 1 |
| Ashley, S; Bhatti, R; Camburn, T; Chan, S; Davidson, N; Johnston, SR; Miles, D; Nouras, H; Shehata, M; Sutherland, S; Wardley, A | 1 |
| Aird, KM; Devi, GR; Ghanayem, RB; Lyerly, HK; Peplinski, S | 1 |
| Fukuoka, M; Kiniwa, M; Nakagawa, K; Okamoto, I; Takezawa, K; Tanizaki, J; Tsukioka, S; Uchida, J | 1 |
| Huang, W; Jia, H; Ma, J; Tan, L; Wu, J; Yan, H; Yang, S; Zeng, M; Zhu, X; Zuo, Y | 1 |
| Altieri, V; De Placido, S; Di Carlo, A; Di Lorenzo, G; Ferro, M; Giordano, A; Macchia, V; Mariano, A; Mazzarella, C; Terracciano, D | 1 |
| Chan, AT; Cheng, SH; Ho, K; Lau, CP; Lei, KI; Lui, VW; Mok, TS; Ng, MH; Tsang, CM; Tsao, SW | 1 |
| Buchanan, SG; Dekoning, T; Eagleson, B; Essenburg, C; Kang, L; Kaufman, D; Staal, B; Su, Y; Vande Woude, GF; West, R; Zhang, YW | 1 |
| Alberts, DS; Baker, AF; Brewer, MA; Chambers, SK; Clouser, MC; Cohen, JL; Cui, H; Gordon, AN; Gordon, MS; Hatch, KD; Isaacs, JD; Janicek, MF; Nagle, RB; Roe, DJ; Wright, HM | 1 |
| Akar, U; Arun, BK; Hortobagyi, GN; LaFortune, TA; Nieves-Alicea, R; Tari, AM; Ueno, NT; Zhang, D | 1 |
| de Weger, RA; Moelans, CB; van Diest, PJ | 1 |
| Azzariti, A; Colucci, G; Fratto, ME; Galluzzo, S; Maiello, E; Santini, D; Silvestris, N; Tommasi, S; Tonini, G; Vincenzi, B; Zoccoli, A | 1 |
| Abbruzzi, A; Chen, C; Come, S; Dang, CT; Dickler, M; Fleisher, M; Hudis, CA; Lehman, R; Lin, N; McArthur, HL; Morris, PG; Moy, B; Norton, L; Patil, S; Steingart, R; Sugarman, S; Winer, E | 1 |
| Dragnev, KH; Graham, RM; Memoli, VA; Petty, WJ; Swift, CB; Urbanic, JJ; Varela, VA; Voelzke, WR; Waller, LL | 1 |
| Fujita, Y; Hiroshima, K; Niijima, M; Nishio, K; Saitoh, M; Takiguchi, Y; Tatsumi, K | 1 |
| Gooding, WE; Grandis, JR; Gubish, CT; Siegfried, JM; Stabile, LP; Xu, H | 1 |
| He, BF; Huang, BY; Luo, RC; Sun, AM; Wang, WJ; Zheng, XK | 1 |
| Hashimoto, K; Komune, S; Nakano, T; Nakashima, T; Oda, Y; Oyama, M; Shiratsuchi, H; Tamiya, S; Yamamoto, H | 1 |
| Chen, H; Cui, B; Jin, Y; Wang, X; Yu, Z | 1 |
| Amagai, K; Baba, H; Bando, H; Denda, T; Fukase, K; Hazama, S; Kato, T; Mishima, H; Muro, K; Shi, X; Skamoto, J; Yamaguchi, K | 1 |
| Biswas-Baldwin, N; Bourhis, J; Carracedo, C; Compton, N; Cupissol, D; De Raucourt, D; Del Campo, JM; Downie, L; El-Hariry, I; Harrington, KJ; Hitt, R; Lokanatha, D; Maroudias, N; Midwinter, D; Nutting, CM; Sebastian, P; Temam, S | 1 |
| Buysschaert, I; Carmeliet, P; Christensen, IJ; Høyer-Hansen, G; Ladekarl, M; Lassen, U; Olesen, RK; Pappot, H; Pfeiffer, P; Rohrberg, KS; Skov, BG; Sørensen, M | 1 |
| Higashiyama, M; Kimura, T; Kiura, K; Kondoh, K; Kudoh, S; Minami, Y; Mitsudomi, T; Noguchi, M; Nokihara, H; Oda, M; Ohe, Y; Saito, H; Tachibana, K; Takeuchi, S; Tanaka, H; Uramoto, H; Yamada, T; Yano, S; Yasumoto, K; Yatabe, Y; Yokota, J; Yoshida, J | 1 |
| Bubley, GJ; Buckle, GC; Choueiri, TK; Eisenberger, MA; Hahn, NM; Hutson, TE; Jacobus, S; Kantoff, PW; Kim, WY; Morrissey, SC; Mortazavi, A; Petrylak, DP; Quinn, DI; Rosenberg, JE; Ross, RW; Ryan, CW; Sonpavde, G; Taplin, ME; Vaishampayan, U; Yu, EY | 1 |
| Fujii, M; Hasegawa, Y; Ijichi, K; Kondo, E; Maseki, S; Murakami, S; Nakanishi, H; Ogawa, T; Tanaka, H | 1 |
| Azria, D; Bascoul-Mollevi, C; Campigna, E; Chardès, T; Coelho, M; Gaborit, N; Larbouret, C; Mach, JP; Pèlegrin, A; Robert, B | 1 |
| Aglietta, M; Cavalloni, G; Gammaitoni, L; Leone, F; Marchiò, S; Migliardi, G; Peraldo-Neia, C; Sarotto, I; Soster, M | 1 |
| Deng, BG; Guo, XF; Zhong, GS; Zhu, XF | 1 |
| Aiba, S; Fujimura, T; Haga, T; Hashimoto, A; Hidaka, T; Mizuashi, M; Onami, K; Watabe, A | 1 |
| Bagnardi, V; Bertolini, F; Calleri, A; Cancello, G; Colleoni, M; Dellapasqua, S; Goldhirsch, A; Intra, M; Luini, A; Montagna, E; Pastrello, D; Perri, G; Rampinelli, C; Veronesi, P; Viale, G | 1 |
| Chang, YC; Chang, YL; Hu, FC; Lee, YC; Shih, JY; Wu, JY; Wu, SG; Yang, PC; Yu, CJ | 1 |
| Ai, Z; Teng, Y; Tong, J; Wang, J; Xu, Y | 1 |
| Amonkar, MM; Diaz, JR; Forbes, CA; Kleijnen, J; Lykopoulos, K; Rea, DW; Riemsma, R | 1 |
| Baldi, A; Citro, G; Fanciulli, M; Spugnini, EP | 1 |
| Bible, KC | 1 |
| Awada, A; Bastholt, L; Bonichon, F; de la Fouchardiere, C; Gómez, JM; Krause, T; Leboulleux, S; Leenhardt, L; Licour, M; Schlumberger, MJ; Soufflet, C; Tennvall, J | 1 |
| Ai, Z; Teng, Y; Wang, J; Xu, Y; Yan, Y | 1 |
| Adam-Klages, S; Arnold, N; Caliebe, A; Eckmann-Scholz, C; Fredrik, R; Hilpert, F; Ma, Y; Schem, C; Sebens, S; Weimer, J | 1 |
| Goldberg, GL; Hazan, R; Horwitz, SB; Hou, JY; McDaid, HM; Rodriguez-Gabin, A; Samaraweera, L; Samaweera, L | 1 |
| Aldana, GQ; DE LA Cámara Gómez, J; Fernández, MJ; Fernández, MS; Folgar, SC; López, MR; López, R; Méndez, CM; Reinoso, CR; Vázquez, MR | 1 |
| Selam, M | 1 |
| Arbel, R; Ben-Bassat, H; Hartzstark, Z; Klein, BY; Laufer, N; Levitzki, R; Rojansky, N | 1 |
| Ackland, SP; Howitt, IJ; McCluskey, A; Sakoff, JA | 1 |
| Bekele, BN; Doan, D; El-Naggar, AK; Holsinger, FC; Jasser, SA; Kim, S; Mandal, M; McMurphy, AB; Myers, JN; Schiff, BA; Sherman, SI; Yeung, SC; Yigitbasi, OG; Younes, MN; Zhou, G | 1 |
| Hirakawa, K; Ishikawa, T; Nobuhara, Y; Ogisawa, K; Onoda, N; Takashima, T; Yamasaki, M; Yamashita, Y | 1 |
| Carpentier, AF; Delattre, JY; Hoang-Xuan, K; Marie, Y; Omuro, AM; Sanson, M; Thillet, J | 1 |
| Arciero, CA; Chen, X; Darcy, KM; Decesare, SL; Godwin, AK; Lee, RB; Lewandowski, G; Schilder, RJ; Sill, MW; Wu, H | 1 |
| Ajiki, T; Digiovanni, J; Kawamoto, T; Kiguchi, K; Ruffino, L | 1 |
| Amadori, D; Brigliadori, G; Fabbri, F; Granato, AM; Rosetti, M; Tesei, A; Ulivi, P; Vannini, I; Zoli, W | 1 |
| Bidart, JM; Duvillard, P; Lacroix, L; Motté, N; Pautier, P; Saulnier, P; Soria, JC | 1 |
| Guo, M; Herman, JG; Liu, S; Lu, F; Zhuang, H | 1 |
| Bisonni, R; Leon, A; Lippe, P; Lombardo, M; Marcucci, F; Massacesi, C; Mattioli, R; Pilone, A; Rocchi, MB; Terrazzino, S | 1 |
| Halgunset, J; Larsson, E; Skogseth, H | 1 |
| Albanell, J; Baselga, J; Doi, T; Koizumi, W; Ohtsu, A; Ramon Cajal, S; Ramon y Cajal, S; Rojo, F; Shirao, K; Tabernero, J; Takiuchi, H; Van Cutsem, E | 1 |
| Asada, K; Chida, K; Hasegawa, H; Naito, T; Suda, T | 1 |
| Burchert, A; Dietrich, C; Gläser, S; Hoffmann, S; Lingelbach, S; Müller, H; Rothmund, M; Wunderlich, A; Zielke, A | 1 |
| Bergh, A; Halin, S; Hammarsten, P; Henriksson, R; Rudolfsson, SH; Wikstöm, P | 1 |
| Barrow, D; Burmi, RS; Gee, JM; Hutcheson, IR; Jones, HE; Knowlden, JM; McClelland, RA; Nicholson, RI | 1 |
| Chen, MJ; Hsu, JM; Kan, SF; Pu, HF; Wang, PS; Yu, CH | 1 |
| Aakre, ME; Arteaga, CL; Bonine-Summers, AR; Brown, KA; Cheng, N; Moses, HL; Pietenpol, JA | 1 |
| Koldenhof, JJ; Sigurdsson, V; Tjin-A-ton, ML; van Montfrans, C; Voest, EE; Witteveen, PO | 1 |
| Fooshee, D; Gomez-Rivera, F; Jasser, SA; Kim, S; Myers, JN; Santillan-Gomez, AA; Younes, MN; Zhao, M | 1 |
| Czaykowski, PM | 1 |
| Nguyen, D; Parr, AL; Steinberg, SM; Tan, AR; Yang, SX | 1 |
| Aguilera, J; Chang, C; Chen, JS; Lopez, JP; Ongkeko, WM; Pardo, FS; Wang-Rodriguez, J | 1 |
| Matuszczak, J; Rajebi, MR; Saif, MW; Shahrokni, A | 1 |
| Fujisaki, R; Gu, Z; Horii, A; Inomata, K; Inoue, A; Kondo, T; Nukiwa, T; Sakurada, A; Sato, M; Yamanaka, S | 1 |
| Aguilera, J; Chang, CY; Lopez, JP; Ongkeko, WM; Pardo, FS; Sneh, G; Wang-Rodriguez, J; Yu, MA | 1 |
| Sherman, SI | 1 |
| Cao, S; Rustum, YM; Yin, MB | 1 |
| Banks, SD; Barrett, LL; Dickerson, S; Pendergast, W; Smith, GK; Waters, KA | 1 |
| Kéri, G; Kökösi, J; Kövesdi, I; Mák, M; Orfi, L; Szász, G; Teplán, I | 1 |
| Ferone, R; Hanlon, MH | 1 |
| Navarro-Blasco, FJ | 1 |
| Aingorn, E; de-Groot, N; Elkin, M; Hochberg, A; Nagler, A; Pines, M; Reich, R; Vlodavsky, I | 1 |
| Avallone, A; Casaretti, R; Catalano, G; Comella, G; Comella, P; De Lucia, L; De Vita, F; Orditura, M; Palmeri, S; Rivellini, F | 1 |
| Griffin, RJ; Ogawa, A; Song, CW | 1 |
| Bergström, JD; Heldin, NE; Westermark, B | 1 |
| Depisch, D; Haider, K; Kornek, GV; Kwasny, W; Penz, M; Raderer, M; Salek, T; Scheithauer, W; Ulrich-Pur, H | 1 |
| Amir, C; Bowers, G; Dent, P; Hewitt, T; Lammering, G; Mikkelsen, RB; Reardon, D; Schmidt-Ullrich, RK; Valerie, K | 1 |
| Bennett, TA; Bergmann-Leitner, ES; Hacker, NF; Stetler-Stevenson, WG; Stromberg, K | 1 |
| Reimer, P; Rückle-Lanz, H | 1 |
| Bamburg, JR; Bedford, JS; Bernstein, BW; Jha, MN | 1 |
| Arteaga, CL; Carter, MB; Chinratanalab, W | 1 |
| Stratford, IJ; Telfer, BA; Wedge, SR; Williams, KJ | 1 |
| Carey, RW; Clamon, GH; Costanza, ME; Dawson, NA; Korzun, AH; Norton, L; Pollak, M; Vogelzang, NJ | 1 |
| Assaraf, YG; Molina, A; Schimke, RT | 1 |
| Curtin, NJ; Harris, AL | 1 |
| Huang, PC; Modest, EJ; Papathanasopoulos, N; Rosowsky, A | 1 |
| Modest, EJ; Rosowsky, A | 1 |
15 review(s) available for quinazolines and Carcinoma
| Article | Year |
|---|---|
CD30+ lymphoproliferative disorder in a patient with metastatic papillary thyroid carcinoma.
Topics: Aged; Carcinoma; Carcinoma, Papillary; Humans; Immunohistochemistry; Ki-1 Antigen; Lymphoma, Large-Cell, Anaplastic; Lymphoproliferative Disorders; Male; Neoplasms, Multiple Primary; Piperidines; Quinazolines; Skin Neoplasms; Thoracic Wall; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2016 |
Risk of rash associated with vandetanib treatment in non-small-cell lung cancer patients: A meta-analysis of 9 randomized controlled trials.
Topics: Antineoplastic Agents; Carcinoma; Carcinoma, Non-Small-Cell Lung; Exanthema; Humans; Incidence; Inflammatory Breast Neoplasms; Neoplasm Staging; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Severity of Illness Index | 2017 |
Targeting HER2 in ovarian and uterine cancers: challenges and future directions.
Topics: Adenocarcinoma, Mucinous; Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma; Endometrial Neoplasms; Female; Genes, erbB-2; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Ovarian Neoplasms; Quinazolines; Trastuzumab; Uterine Neoplasms | 2014 |
Targeting HER2 for the treatment of breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma; Female; Humans; Lapatinib; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab; Triazoles | 2015 |
Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Carcinoma; Female; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2 | 2010 |
ZD6474, a small molecule tyrosine kinase inhibitor, potentiates the anti-tumor and anti-metastasis effects of radiation for human nasopharyngeal carcinoma.
Topics: Animals; Apoptosis; Carcinoma; Chemotherapy, Adjuvant; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; Neoplasm Metastasis; Piperidines; Protein Kinase Inhibitors; Quinazolines | 2010 |
Targeting EGFR in bilio-pancreatic and liver carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Biliary Tract Neoplasms; Carcinoma; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Liver Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib | 2011 |
Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease Progression; Female; Humans; Lapatinib; Letrozole; Neoadjuvant Therapy; Neoplasm Metastasis; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Cytoplasmic and Nuclear; Triazoles | 2012 |
Preclinical models in electrochemotherapy: the role of veterinary patients.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cat Diseases; Cats; Cisplatin; Dog Diseases; Dogs; Drug Evaluation, Preclinical; Electrochemotherapy; Epirubicin; Head and Neck Neoplasms; Melanoma; Mitoxantrone; Neoplasms; Quinazolines; Sarcoma; Thiophenes | 2012 |
Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Insulin Receptor Substrate Proteins; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Phosphoproteins; Quinazolines; Signal Transduction | 2006 |
Early clinical studies of novel therapies for thyroid cancers.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Carcinoma; Clinical Trials as Topic; Drug Delivery Systems; Gefitinib; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Sorafenib; Thyroid Neoplasms | 2008 |
The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells.
Topics: Autocrine Communication; Benzothiazoles; Breast Neoplasms; Carcinoma; Epidermal Growth Factor; ErbB Receptors; Female; Genes, erbB; Growth Substances; Humans; Neuregulin-1; Quinazolines; Radiation, Ionizing; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Signal Transduction; Tumor Cells, Cultured; Tyrphostins | 2001 |
[New therapeutic options in chemotherapy of advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Tegafur; Thiophenes; Uracil | 2001 |
Inhibitors of HER2/neu (erbB-2) signal transduction.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Proto-Oncogene Mas; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2001 |
Synthesis and biological activity of tricyclic antifolate compounds with fixed geometry.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma; Cell Line; Chickens; Enterococcus faecalis; Folic Acid Antagonists; Humans; Leukemia L1210; Liver; Malaria; Mammary Neoplasms, Experimental; Mice; Mouth Neoplasms; Pyrimethamine; Quinazolines; Structure-Activity Relationship | 1971 |
25 trial(s) available for quinazolines and Carcinoma
| Article | Year |
|---|---|
Metastatic nasopharyngeal carcinoma outcomes in patients on cisplatin with nolatrexed or 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Quinazolines; Survival Rate; Treatment Outcome | 2014 |
Phase I study of cisplatin, hyperthermia, and lapatinib in patients with recurrent carcinoma of the uterine cervix in a previously irradiated area.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Humans; Hyperthermia, Induced; Lapatinib; Neoplasm Recurrence, Local; Quinazolines; Treatment Outcome; Uterine Cervical Neoplasms | 2015 |
A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzodioxoles; Carcinoma; Disease Progression; Disease-Free Survival; Early Termination of Clinical Trials; Female; Humans; Male; Middle Aged; Quinazolines; Radiography; Response Evaluation Criteria in Solid Tumors; src-Family Kinases; Survival Rate; Thymoma; Thymus Neoplasms; Treatment Failure; Young Adult | 2015 |
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Estrogen Receptor alpha; Female; Gene Expression; Humans; Immunoglobulin G; Lapatinib; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; RNA, Messenger; Trastuzumab; Treatment Outcome; Tumor Microenvironment; Tumor Suppressor Protein p53; Young Adult | 2016 |
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Letrozole; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Risk Assessment; Survival Analysis; Treatment Outcome; Triazoles | 2009 |
Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Female; Genes, erbB-2; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Probability; Prognosis; Proportional Hazards Models; Quinazolines; Survival Analysis; Treatment Outcome | 2009 |
Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Quinazolines; Survival Rate; Young Adult | 2009 |
Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antineoplastic Agents; Blood Pressure; Carcinoma; Chi-Square Distribution; Female; Humans; Hypertension; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Protein Kinase Inhibitors; Proteinuria; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome | 2010 |
Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Humans; Likelihood Functions; Ovarian Neoplasms; Platinum Compounds; Prognosis; Quinazolines; Treatment Outcome; Tumor Microenvironment; Up-Regulation; Vascular Endothelial Growth Factor A | 2010 |
Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Breast Neoplasms; C-Reactive Protein; Carcinoma; Dose-Response Relationship, Drug; Feasibility Studies; Female; Humans; Lapatinib; Middle Aged; Quinazolines; Stroke Volume; Trastuzumab; Troponin I | 2011 |
Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: results from the randomised phase II part of a phase I/II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Fluorouracil; Humans; Japan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Treatment Outcome; Vascular Endothelial Growth Factor A | 2012 |
Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Disease Progression; Female; Head and Neck Neoplasms; Humans; Lapatinib; Male; Middle Aged; Neoadjuvant Therapy; Neoplasms, Squamous Cell; Placebos; Quinazolines; Single-Blind Method; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2011 |
Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Prospective Studies; Quinazolines; Survival Analysis; Treatment Outcome | 2012 |
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Piperidines; Platinum Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Risk Factors; Taxoids; Treatment Failure; Urologic Neoplasms; Urothelium | 2012 |
Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.
Topics: Administration, Metronomic; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Pharmacological; Breast Neoplasms; Capecitabine; Carcinoma; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplastic Stem Cells; Quinazolines; Receptor, ErbB-2; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.
Topics: Adenocarcinoma, Follicular; Adolescent; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Papillary; Diarrhea; Disease-Free Survival; Double-Blind Method; Electrocardiography; ErbB Receptors; Female; Heart Conduction System; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Survival Analysis; Thyroid Cancer, Papillary; Thyroid Neoplasms; Young Adult | 2012 |
Phase II trial of erlotinib plus capecitabine as first-line treatment for metastatic pancreatic cancer (XELTA study).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines | 2013 |
Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Catalytic Domain; Cloning, Molecular; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Exons; Female; Gefitinib; Humans; Immunohistochemistry; Middle Aged; Mutation; Ovarian Neoplasms; Peritoneal Neoplasms; Polymerase Chain Reaction; Protein Structure, Tertiary; Quinazolines; Recurrence; Time Factors; Treatment Outcome | 2005 |
Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Ovarian Neoplasms; Paclitaxel; Quinazolines; Treatment Outcome | 2006 |
Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbon-Nitrogen Ligases; Carcinoma; Colorectal Neoplasms; Diarrhea; Fatigue; Female; Genotype; Glucuronosyltransferase; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neutropenia; Polymorphism, Genetic; Predictive Value of Tests; Promoter Regions, Genetic; Quinazolines; Thiophenes; Thymidylate Synthase; Vomiting | 2006 |
Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Area Under Curve; Biomarkers, Tumor; Carcinoma; ErbB Receptors; Female; Gefitinib; Humans; Ki-67 Antigen; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Stomach Neoplasms | 2006 |
Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment.
Topics: Acneiform Eruptions; Antineoplastic Agents; Biomarkers; Biopsy; Breast Neoplasms; Carcinoma; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Folliculitis; Gene Expression Profiling; Humans; Ki-67 Antigen; Mitogen-Activated Protein Kinases; Neoplasm Proteins; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Skin | 2008 |
Oxaliplatin and raltitrexed combined with leucovorin-modulated 5-fluorouracil i.v. bolus every two weeks: a dose finding study in advanced previously treated colorectal carcinoma. Southern Italy Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Rectal Neoplasms; Thiophenes; Treatment Outcome | 2000 |
Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma: results of a Phase I-II trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Enzyme Inhibitors; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Quinazolines; Survival Rate; Thiophenes; Thymidylate Synthase | 2001 |
Trimetrexate in untreated and previously treated patients with metastatic breast cancer: a Cancer and Leukemia Group B study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Humans; Liver Neoplasms; Middle Aged; Quinazolines; Trimetrexate | 1991 |
100 other study(ies) available for quinazolines and Carcinoma
| Article | Year |
|---|---|
Discovery of Orally Bioavailable SOS1 Inhibitors for Suppressing KRAS-Driven Carcinoma.
Topics: Animals; Carbon Isotopes; Carcinoma; Dogs; Humans; Mice; Nuclear Family; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Quinazolines; SOS1 Protein | 2022 |
Design and Structural Optimization of Orally Bioavailable SOS1 Inhibitors for the Treatment of KRAS-Driven Carcinoma.
Topics: Animals; Carcinoma; Humans; Mice; Proto-Oncogene Proteins p21(ras); Quinazolines; SOS1 Protein | 2022 |
Hyperthermic intraperitoneal chemotherapy with recombinant mutant human TNF-α and raltitrexed in mice with colorectal-peritoneal carcinomatosis.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Colorectal Neoplasms; HCT116 Cells; Humans; Injections, Intraperitoneal; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Peritoneal Neoplasms; Quinazolines; Recombinant Proteins; Thiophenes; Tumor Necrosis Factor-alpha | 2020 |
Evodiamine Induces Cell Growth Arrest, Apoptosis and Suppresses Tumorigenesis in Human Urothelial Cell Carcinoma Cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinogenesis; Carcinoma; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Fluorescein-5-isothiocyanate; Fluorouracil; Humans; Mutation; Plant Extracts; Quinazolines; Signal Transduction; Urinary Bladder Neoplasms; Urothelium | 2017 |
A study of peritoneal metastatic xenograft model of colorectal cancer in the treatment of hyperthermic intraperitoneal chemotherapy with Raltitrexed.
Topics: Absorption, Physiological; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Half-Life; Hot Temperature; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; Mice, Nude; Peritoneal Neoplasms; Quinazolines; Random Allocation; Thiophenes; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Construction of EGFR peptide gefitinib/quantum dots long circulating polymeric liposomes for treatment and detection of nasopharyngeal carcinoma.
Topics: Antineoplastic Agents; Carcinoma; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gefitinib; Humans; Liposomes; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Peptides; Polymers; Quantum Dots; Quinazolines; Structure-Activity Relationship; Tumor Cells, Cultured | 2017 |
Detection of epidermal growth factor receptor mutation in the peripheral blood of patients with esophageal carcinoma to guide epidermal growth factor receptor-tyrosine kinase inhibitor treatment.
Topics: Adult; Aged; Alleles; Antineoplastic Agents; Carcinoma; Disease Progression; DNA Mutational Analysis; ErbB Receptors; Esophageal Neoplasms; Female; Gefitinib; Humans; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2018 |
Rare complications of multikinase inhibitor treatment.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Carcinoma, Medullary; Female; Follow-Up Studies; Heart Failure; Humans; Intestinal Perforation; Kaplan-Meier Estimate; Male; Middle Aged; Oophoritis; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines; Retrospective Studies; Risk Factors; Sorafenib; Thrombocytopenia; Thyroid Neoplasms; Time Factors; Young Adult | 2018 |
Evodiamine in combination with histone deacetylase inhibitors has synergistic cytotoxicity in thyroid carcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Quinazolines; Reactive Oxygen Species; Thyroid Neoplasms | 2019 |
Cancer stem-like cell properties are regulated by EGFR/AKT/β-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma.
Topics: Animals; Antineoplastic Agents; beta Catenin; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cisplatin; ErbB Receptors; Gefitinib; Gene Knockdown Techniques; Homeodomain Proteins; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nanog Homeobox Protein; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Transplantation; Neoplastic Stem Cells; Proto-Oncogene Proteins c-akt; Quinazolines; Side-Population Cells; Signal Transduction; Spheroids, Cellular; Xenograft Model Antitumor Assays | 2013 |
Molecular profiling for druggable genetic abnormalities in carcinoma of unknown primary.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arginine; Biopsy; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Immunohistochemistry; Leucine; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Neoplasms, Unknown Primary; Point Mutation; Quinazolines; Tomography, X-Ray Computed | 2013 |
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Topics: Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperidines; Pleural Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2014 |
Indomethacin promotes apoptosis in gastric cancer cells through concomitant degradation of Survivin and Aurora B kinase proteins.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Apoptosis; Aurora Kinase B; Carcinoma; Cell Line, Tumor; Gastric Mucosa; Humans; Indomethacin; Inhibitor of Apoptosis Proteins; Mice, Inbred C57BL; Organophosphates; Protein Kinase Inhibitors; Quinazolines; Stomach Neoplasms; Survivin | 2014 |
Resveratrol analogue (E)-8-acetoxy-2-[2-(3,4-diacetoxyphenyl)ethenyl]-quinazoline induces G₂/M cell cycle arrest through the activation of ATM/ATR in human cervical carcinoma HeLa cells.
Topics: Ataxia Telangiectasia Mutated Proteins; Carcinoma; CDC2 Protein Kinase; cdc25 Phosphatases; Cell Cycle Checkpoints; Cell Division; Checkpoint Kinase 1; Checkpoint Kinase 2; Cyclin B1; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; DNA Damage; Female; G2 Phase; HeLa Cells; Humans; Phosphorylation; Protein Kinases; Quinazolines; Resveratrol; Signal Transduction; Stilbenes; Tumor Suppressor Protein p53; Up-Regulation; Uterine Cervical Neoplasms | 2015 |
Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe.
Topics: Animals; Antineoplastic Agents; Aurora Kinase A; Aurora Kinase B; Carcinoma; Cell Cycle Proteins; Cyclohexanecarboxylic Acids; Drug Synergism; Female; HeLa Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Mitosis; Molecular Targeted Therapy; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Organophosphates; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Quinazolines; Thiazoles; Tumor Cells, Cultured | 2015 |
Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma; Cell Cycle; Cell Line, Tumor; DNA, Neoplasm; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; High-Throughput Screening Assays; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mice; Molecular Targeted Therapy; Mutation; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Small Molecule Libraries; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Gastrointestinal Neoplasms; Gene Amplification; Gene Expression; Gene Knockdown Techniques; Humans; Lapatinib; Mice; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Trastuzumab; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Lysophosphatidic acid induces both EGFR-dependent and EGFR-independent effects on DNA synthesis and migration in pancreatic and colorectal carcinoma cells.
Topics: Carcinoma; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; DNA; ErbB Receptors; Gefitinib; HCT116 Cells; HT29 Cells; Humans; Lysophospholipids; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Transcriptional Activation | 2016 |
Evodiamine inhibits the migration and invasion of nasopharyngeal carcinoma cells in vitro via repressing MMP-2 expression.
Topics: Blotting, Western; Carcinoma; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Survival; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Molecular Structure; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; NF-kappa B; Phosphorylation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2015 |
Intravoxel Incoherent Motion Diffusion-weighted Magnetic Resonance Imaging for Monitoring the Early Response to ZD6474 from Nasopharyngeal Carcinoma in Nude Mouse.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Diffusion Magnetic Resonance Imaging; Humans; Image Processing, Computer-Assisted; Ki-67 Antigen; Mice; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Piperidines; Quinazolines; Radiography; Transplantation, Heterologous | 2015 |
Human epidermal growth factor receptor 2/neu as a novel therapeutic target in sinonasal undifferentiated carcinoma.
Topics: Animals; Carcinoma; Cell Line, Tumor; Humans; Lapatinib; Male; Maxillary Sinus Neoplasms; Mice; Mice, Nude; Polymorphism, Single Nucleotide; Quinazolines; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2016 |
In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasms, Experimental; Quinazolines; Structure-Activity Relationship | 2016 |
Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder.
Topics: Aminosalicylic Acids; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma; CCAAT-Enhancer-Binding Protein-delta; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Multidrug Resistance-Associated Protein 2; Paclitaxel; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Urinary Bladder Neoplasms; Urothelium | 2017 |
Effect of Vandetanib on Lung Tumorigenesis in Transgenic Mice Carrying an Activating Egfr Gene Mutation.
Topics: Animals; Antineoplastic Agents; Carcinogenesis; Carcinoma; ErbB Receptors; Gene Expression Regulation; Hyperplasia; Lung Neoplasms; Mice; Mice, Transgenic; Mutation; Piperidines; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A | 2016 |
Inhibition of eEF-2 kinase sensitizes human nasopharyngeal carcinoma cells to lapatinib-induced apoptosis through the Src and Erk pathways.
Topics: Apoptosis; Carcinoma; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Elongation Factor 2 Kinase; Extracellular Signal-Regulated MAP Kinases; Gene Silencing; Humans; Lapatinib; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Protein Kinase Inhibitors; Quinazolines; RNA Interference; Signal Transduction; src-Family Kinases | 2016 |
Inhibition of vascular endothelial growth factor signalling using cediranib (RECENTIN; AZD2171) enhances radiation response and causes substantial physiological changes in lung tumour xenografts.
Topics: Animals; Apoptosis; Carcinoma; Combined Modality Therapy; Female; Lung Neoplasms; Mice; Mice, Nude; Necrosis; Quinazolines; Vascular Endothelial Growth Factor A | 2008 |
Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Proliferation; Cell Survival; Colonic Neoplasms; Drug Evaluation, Preclinical; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imidazoles; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Receptor Cross-Talk; Receptor, IGF Type 1; Signal Transduction; Tumor Cells, Cultured | 2008 |
Role of epidermal growth factor gene in the development of pancreatic cancer and efficiency of inhibitors of this gene in the treatment of pancreatic carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Proliferation; Drug Evaluation, Preclinical; Epidermal Growth Factor; ErbB Receptors; Fluorouracil; Gene Frequency; Genetic Predisposition to Disease; Humans; Pancreatic Neoplasms; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Quinazolines; Time Factors; Tumor Cells, Cultured; Tyrphostins | 2008 |
Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib.
Topics: Aged; Carcinoma; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Thyroid Neoplasms; Tomography, X-Ray Computed | 2009 |
Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Case-Control Studies; Cell Death; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Female; Forkhead Box Protein M1; Forkhead Box Protein O3; Forkhead Transcription Factors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Quinazolines; RNA, Small Interfering; Tumor Cells, Cultured | 2009 |
Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer.
Topics: Antineoplastic Agents; Benzodioxoles; Carcinoma; Carcinoma, Papillary; Cell Culture Techniques; Cell Proliferation; Drug Delivery Systems; Drug Evaluation, Preclinical; Enzyme Activation; Focal Adhesion Protein-Tyrosine Kinases; Humans; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins pp60(c-src); Quinazolines; Thyroid Neoplasms; Tumor Cells, Cultured | 2009 |
Enediyne lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A431 cells and lung carcinoma H460 cells.
Topics: Aminoglycosides; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Enediynes; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2009 |
Antiproliferation and apoptosis induced by evodiamine in human colorectal carcinoma cells (COLO-205).
Topics: Anticarcinogenic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma; Caspase 3; Cell Cycle; Cell Proliferation; Colorectal Neoplasms; Evodia; G2 Phase; Humans; Membrane Potentials; Mitochondria; Plant Extracts; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2009 |
The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines | 2009 |
[A case of meningeal carcinomatosis of lung adenocarcinoma well controlled by re-treatment with gefitinib].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Drug Resistance, Neoplasm; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Meningeal Neoplasms; Mutation; Paclitaxel; Quinazolines | 2009 |
New platform for controlled and sustained delivery of the EGF receptor tyrosine kinase inhibitor AG1478 using poly(lactic-co-glycolic acid) microspheres.
Topics: Animals; Carcinoma; Cell Line; Cell Line, Tumor; Enzyme Inhibitors; ErbB Receptors; Humans; Lactic Acid; Microspheres; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Protein-Tyrosine Kinases; Quinazolines; Rats; Tyrphostins | 2010 |
Activity of the kinesin spindle protein inhibitor ispinesib (SB-715992) in models of breast cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Kinesins; Mice; Mice, Nude; Mice, SCID; Quinazolines; Xenograft Model Antitumor Assays | 2010 |
Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Capecitabine; Carcinoma; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Genes, erbB-2; Health Services Accessibility; Humans; Lapatinib; Middle Aged; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome; United Kingdom | 2010 |
X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor.
Topics: Antineoplastic Agents; Apoptosis; Benzoquinones; Breast Neoplasms; Carcinoma; Cells, Cultured; Down-Regulation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; ErbB Receptors; Feasibility Studies; Female; Gene Expression Regulation, Neoplastic; Humans; Mastitis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Sulfones; X-Linked Inhibitor of Apoptosis Protein | 2010 |
Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplification.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Drug Combinations; Drug Delivery Systems; Drug Synergism; Fluorouracil; Gene Amplification; Humans; Lapatinib; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Oxonic Acid; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Tegafur; Trastuzumab; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on androgen-independent prostate cancer PC-3 cell line growth and NSE, chromogranin A and osteopontin content.
Topics: Androgens; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Carcinoma; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Chromogranin A; Cytosol; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Male; Osteopontin; Prostatic Neoplasms; Quinazolines; Receptor, ErbB-2 | 2010 |
Anti-invasion, anti-proliferation and anoikis-sensitization activities of lapatinib in nasopharyngeal carcinoma cells.
Topics: Anoikis; Antineoplastic Agents; Carcinoma; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Humans; Lapatinib; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2011 |
MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth.
Topics: Animals; Carcinoma; Cell Cycle; Cell Growth Processes; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Hepatocyte Growth Factor; Humans; Mice; Mice, Inbred C3H; Mice, SCID; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyridazines; Quinazolines; Receptors, Growth Factor; Triazoles; Xenograft Model Antitumor Assays | 2010 |
Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser¹⁰ p27 phosphorylation in epidermal growth factor receptor-expressing breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Female; Gene Silencing; Genes, erbB-1; Humans; Mice; Mice, Nude; Phosphorylation; Protein Binding; Protein Kinases; Quinazolines; RNA, Small Interfering; Serine; Stathmin; Xenograft Model Antitumor Assays | 2010 |
Chromosome 17 polysomy without HER2 amplification does not predict response to lapatinib in metastatic breast cancer--letter.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Chromosomes, Human, Pair 17; Female; Gene Amplification; Humans; Lapatinib; Neoplasm Metastasis; Polyploidy; Prognosis; Quinazolines; Receptor, ErbB-2 | 2010 |
High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer.
Topics: Animals; Biomarkers, Pharmacological; Carcinoma; Cyclin D1; Cyclin D3; Cyclin E; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gastrointestinal Neoplasms; Gene Expression Profiling; Humans; Immunohistochemistry; Mice; NIH 3T3 Cells; Quinazolines | 2011 |
An early event of EGFR mutation in pleomorphic carcinoma of the lung.
Topics: Antineoplastic Agents; Carcinoma; Cell Transformation, Neoplastic; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Point Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.
Topics: Animals; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Hepatocyte Growth Factor; Humans; Mice; Mice, SCID; Mitogen-Activated Protein Kinases; Neoplasm Invasiveness; Neoplasms, Squamous Cell; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Transforming Growth Factor alpha; Wound Healing; Xenograft Model Antitumor Assays | 2011 |
[Gefitinib enhances the radiosensitivity of nasopharyngeal carcinoma cell line CNE2 in vitro].
Topics: Apoptosis; Carcinoma; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Flow Cytometry; Gefitinib; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Quinazolines; Radiation Tolerance | 2011 |
Tumor-to-tumor metastasis: lung adenocarcinoma metastasizing to a follicular variant of papillary thyroid carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Combined Modality Therapy; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2011 |
Novel irreversible EGFR tyrosine kinase inhibitor 324674 sensitizes human colon carcinoma HT29 and SW480 cells to apoptosis by blocking the EGFR pathway.
Topics: Anilides; Apoptosis; Carcinoma; Cell Proliferation; Colonic Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; HT29 Cells; Humans; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Tyrphostins | 2011 |
Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Hepatocyte Growth Factor; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines | 2011 |
Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3β/snail signalling pathway.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Phenotype; Phosphorylation; Protein Transport; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Snail Family Transcription Factors; Transcription Factors | 2012 |
In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line, Tumor; Cetuximab; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Inhibitory Concentration 50; Kaplan-Meier Estimate; Lapatinib; Mice; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Phosphorylation; Protein Multimerization; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2012 |
Antitumor activity of Src inhibitor saracatinib (AZD-0530) in preclinical models of biliary tract carcinomas.
Topics: Aged; Animals; Antineoplastic Agents; Benzodioxoles; Biliary Tract Neoplasms; Carcinoma; Cell Line, Tumor; Cell Movement; Cell Proliferation; Enzyme Activation; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Neovascularization, Pathologic; Phosphorylation; Quinazolines; src-Family Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Synergism; ErbB Receptors; Esophageal Neoplasms; G2 Phase Cell Cycle Checkpoints; Humans; Lapatinib; M Phase Cell Cycle Checkpoints; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2013 |
Successful treatment of HER-2-positive metastatic apocrine carcinoma of the skin with lapatinib and capecitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Capecitabine; Carcinoma; Deoxycytidine; Fluorouracil; Head and Neck Neoplasms; Humans; Immunohistochemistry; Lapatinib; Liver Neoplasms; Male; Middle Aged; Quinazolines; Receptor, ErbB-2; Scalp; Skin Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Radiography, Thoracic; Time Factors; Treatment Outcome | 2013 |
Epidermal growth factor receptor signaling pathway involved in progestin-resistance of human endometrial carcinoma: In a mouse model.
Topics: Animals; Antineoplastic Agents, Hormonal; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Therapy, Combination; Endometrial Neoplasms; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Medroxyprogesterone Acetate; Mice; Mice, Inbred BALB C; Phosphorylation; Quinazolines; Receptors, Progesterone; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
Treating advanced radioresistant differentiated thyroid cancer.
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Female; Humans; Male; Piperidines; Quinazolines; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2012 |
First do no harm: counting the cost of chasing drug efficacy.
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Female; Humans; Male; Piperidines; Quinazolines; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2012 |
Influence of epidermal growth factor receptor inhibitor AG1478 on epithelial-mesenchymal transition in endometrial carcinoma cells.
Topics: Carcinoma; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Endometrial Neoplasms; Enzyme Inhibitors; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Quinazolines; Tumor Cells, Cultured; Tyrphostins | 2012 |
Aurora kinase inhibitor AZD1152 has an additional effect of platinum on a sequential application at the human ovarian cancer cell line SKOV3.
Topics: Antineoplastic Agents; Apoptosis; Aurora Kinase B; Carboplatin; Carcinoma; Caspase 3; Caspase 7; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Synergism; Female; Humans; Organophosphates; Ovarian Neoplasms; Polyploidy; Quinazolines | 2013 |
Exploiting MEK inhibitor-mediated activation of ERα for therapeutic intervention in ER-positive ovarian carcinoma.
Topics: Animals; Antineoplastic Agents, Hormonal; Benzamides; Carcinoma; Cell Line, Tumor; Diphenylamine; Estradiol; Estrogen Receptor alpha; Extracellular Signal-Regulated MAP Kinases; Feedback, Physiological; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Lapatinib; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Ovarian Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Psoriasis aggravation due to lapatinib.
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Disease Progression; ErbB Receptors; Female; Humans; Lapatinib; Psoriasis; Quinazolines | 2013 |
Inhibitors that target protein kinases for the treatment of ovarian carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Catechols; Cell Cycle; Cell Division; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Nitriles; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Time Factors; Tumor Cells, Cultured; Tyrphostins | 2003 |
Serine/threonine protein phosphatase inhibition enhances the effect of thymidylate synthase inhibition.
Topics: Antimetabolites, Antineoplastic; Cantharidin; Carcinoma; Cell Cycle; Cell Division; Cell Line, Tumor; Colorectal Neoplasms; DNA, Neoplasm; Drug Synergism; Enzyme Inhibitors; HT29 Cells; Humans; Phosphoprotein Phosphatases; Quinazolines; Thymidylate Synthase | 2004 |
Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Carcinoma, Papillary; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Mice; Mice, Nude; Paclitaxel; Phosphorylation; Quinazolines; Thyroid Neoplasms; Transforming Growth Factor alpha; Tumor Cells, Cultured | 2004 |
Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines.
Topics: Animals; Carcinoma; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Transplantation; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Thyroid Neoplasms; Transplantation, Heterologous | 2005 |
EGFR tyrosine kinase domain mutations in human gliomas.
Topics: Astrocytoma; Brain Neoplasms; Carcinoma; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genetic Testing; Glioblastoma; Glioma; Humans; Lung Neoplasms; Mutation; Oligodendroglioma; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines | 2005 |
Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents; Blotting, Western; Body Weight; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Enzyme Inhibitors; ErbB Receptors; Gallbladder; Gallbladder Neoplasms; Gefitinib; Humans; In Situ Nick-End Labeling; MAP Kinase Signaling System; Mice; Mice, Transgenic; Microscopy, Fluorescence; Neoplasms, Experimental; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Tolonium Chloride | 2005 |
Modulation of drug cytotoxicity by Iressa (ZD1839) in pancreatic cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Quinazolines | 2005 |
Gefitinib-sensitizing mutation in esophageal carcinoma cell line Kyse450.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Esophageal Neoplasms; Gefitinib; Humans; Mutation, Missense; Protein Structure, Tertiary; Quinazolines | 2006 |
The invasive behaviour of prostatic cancer cells is suppressed by inhibitors of tyrosine kinase.
Topics: Basement Membrane; Biological Assay; Carcinoma; Cell Movement; Collagen; Drug Combinations; Genistein; Humans; Laminin; Male; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Neoplasm Invasiveness; Plasminogen; Plasminogen Activators; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteoglycans; Quinazolines; Tyrphostins | 2006 |
Lymphangitis carcinomatosis as a potential predictor for a response to gefitinib.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma; Female; Forecasting; Gefitinib; Humans; Lung Neoplasms; Lymphangitis; Male; Quinazolines; Treatment Outcome | 2006 |
Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors--a novel antiproliferative/antiangiogenic strategy in thyroid cancer.
Topics: Carcinoma; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Humans; Piperidines; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Thyroid Neoplasms; Vascular Endothelial Growth Factor A | 2006 |
Inhibitory effects of castration in an orthotopic model of androgen-independent prostate cancer can be mimicked and enhanced by angiogenesis inhibition.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma; Castration; Combined Modality Therapy; Dose-Response Relationship, Drug; Male; Piperidines; Prostatic Neoplasms; Quinazolines; Rats; Xenograft Model Antitumor Assays | 2006 |
Anti-proliferative effects of evodiamine on human prostate cancer cell lines DU145 and PC3.
Topics: Androgens; Apoptosis; Carcinoma; Caspase 3; Caspase 8; Caspase 9; CDC2 Protein Kinase; Cell Division; Cell Line, Tumor; Culture Media; Cyclin B; Cyclin B1; DNA Fragmentation; DNA, Neoplasm; Dose-Response Relationship, Drug; Flow Cytometry; G2 Phase; Humans; L-Lactate Dehydrogenase; Male; Plant Extracts; Prostatic Neoplasms; Purines; Quinazolines; Roscovitine | 2007 |
Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial Cells; ErbB Receptors; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Mammary Glands, Human; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases | 2007 |
[Skin eruptions as an adverse reaction to epidermal growth-factor receptor inhibitors].
Topics: Acneiform Eruptions; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma; Cetuximab; Drug Eruptions; ErbB Receptors; Gefitinib; Humans; Kidney Neoplasms; Male; Melanoma; Middle Aged; Paronychia; Protein Kinase Inhibitors; Quinazolines | 2007 |
The tyrosine kinase inhibitor, AZD2171, inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model.
Topics: Animals; Apoptosis; Carcinoma; Cell Proliferation; Cells, Cultured; Endothelium, Vascular; Humans; Male; Mice; Mice, Nude; Quinazolines; Survival Rate; Thyroid Neoplasms; Umbilical Veins; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2007 |
Therapy of colon carcinoma: an oncology perspective. Interview with Piotr M. Czaykowski by Paul C. Adams.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoembryonic Antigen; Carcinoma; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Quinazolines; Rectal Neoplasms; Thiophenes | 2007 |
Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Blotting, Western; Carcinoma; Cell Line, Tumor; Cell Proliferation; Culture Media; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Fluorescent Antibody Technique; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; In Situ Nick-End Labeling; Neoplasm Proteins; Quinazolines; RNA, Neoplasm; Thyroid Neoplasms | 2007 |
Erlotinib-induced episcleritis in a patient with pancreatic cancer.
Topics: Carcinoma; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Scleritis | 2008 |
siRNA targeting against EGFR, a promising candidate for a novel therapeutic application to lung adenocarcinoma.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma; DNA Mutational Analysis; DNA, Neoplasm; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Silencing; Gene Targeting; Genes, ras; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering | 2008 |
Gefitinib (Iressa) potentiates the effect of ionizing radiation in thyroid cancer cell lines.
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Phosphorylation; Quinazolines; Thyroid Neoplasms | 2008 |
Modulation of target enzyme associated with the action of antifolates.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Dose-Response Relationship, Drug; Drug Interactions; Evaluation Studies as Topic; Humans; Intestinal Neoplasms; Leucovorin; Quinazolines; Thiophenes; Thymidine; Thymidylate Synthase; Tumor Cells, Cultured | 1994 |
Destruction of WiDr multicellular tumor spheroids with the novel thymidylate synthase inhibitor 1843U89 at physiological thymidine concentrations.
Topics: Antineoplastic Agents; Carcinoma; Cell Division; Colonic Neoplasms; Humans; Indoles; Isoindoles; Methotrexate; Quinazolines; Thymidine; Thymidylate Synthase; Time Factors; Tumor Cells, Cultured | 1994 |
Heterocondensed quinazolones: synthesis and protein-tyrosine kinase inhibitory activity of 3,4-dihydro-1H,6H-[1,4] oxazino-[3,4-b]quinazolin-6-one derivatives.
Topics: Antineoplastic Agents; Carcinoma; Colonic Neoplasms; Magnetic Resonance Spectroscopy; Protein-Tyrosine Kinases; Quinazolines; Spectrophotometry, Ultraviolet; Structure-Activity Relationship; Tumor Cells, Cultured | 1996 |
In vitro uptake, anabolism, and cellular retention of 1843U89 and other benzoquinazoline inhibitors of thymidylate synthase.
Topics: Animals; Carcinoma; Enzyme Inhibitors; Folic Acid; Folic Acid Antagonists; Humans; Indoles; Intestinal Neoplasms; Isoindoles; Leucovorin; Liver; Metabolic Clearance Rate; Peptide Synthases; Polyglutamic Acid; Quinazolines; Swine; Thymidylate Synthase; Tumor Cells, Cultured | 1996 |
Alfuzosin is not associated with dermatomyositis.
Topics: Adrenergic alpha-Antagonists; Carcinoma; Dermatomyositis; Humans; Lung Neoplasms; Male; Quinazolines; Time Factors | 1999 |
Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone.
Topics: Animals; Antineoplastic Agents; Carcinoma; Collagen; Dose-Response Relationship, Drug; Drug Combinations; Gelatin; Humans; Laminin; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred C3H; Neoplasm Invasiveness; Neoplasm Transplantation; Piperidines; Promoter Regions, Genetic; Proteoglycans; Quinazolines; Quinazolinones; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 1999 |
A novel drug to reduce tumor perfusion: antitumor effect alone and with hyperthermia.
Topics: Animals; Antineoplastic Agents; Blood Pressure; Carcinoma; Cell Line; Combined Modality Therapy; Hydrogen-Ion Concentration; Hyperthermia, Induced; Mammary Neoplasms, Animal; Mice; Neoplasm Transplantation; Perfusion; Piperazines; Quinazolines; Regional Blood Flow; Rubidium Radioisotopes; Time Factors; Vasoconstrictor Agents | 2000 |
Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells.
Topics: Antineoplastic Agents; Butadienes; Carcinoma; Enzyme Inhibitors; ErbB Receptors; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Kinase Kinase 1; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Nitriles; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-met; Quinazolines; RNA, Messenger; Suramin; Thyroid Neoplasms; Transforming Growth Factor alpha; Tumor Cells, Cultured; Tyrphostins | 2000 |
Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells.
Topics: Antigens, CD; Autocrine Communication; Carcinoma; Cell Adhesion; Cell Movement; Cell Size; DNA, Antisense; DNA, Complementary; Enzyme Induction; Enzyme Inhibitors; ErbB Receptors; Extracellular Matrix Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; Integrin alpha3; Integrin alpha6; Integrins; Laminin; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Neoplasm Proteins; Ovarian Neoplasms; Phenotype; Quinazolines; Signal Transduction; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Transfection; Tumor Cells, Cultured | 2001 |
Caffeine eliminates gamma-ray-induced G2-phase delay in human tumor cells but not in normal cells.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Animals; Breast Neoplasms; Caffeine; Calcium Channel Blockers; Calcium Signaling; Carcinoma; Chickens; Demecolcine; Drug Resistance; Female; Fibroblasts; G2 Phase; Gamma Rays; HeLa Cells; Humans; Mitosis; Neoplastic Stem Cells; Neurons; Ovarian Neoplasms; Phosphodiesterase Inhibitors; Quinazolines; Radiation Tolerance; Ryanodine; Ryanodine Receptor Calcium Release Channel; Thapsigargin; Tumor Cells, Cultured | 2002 |
ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model.
Topics: Animals; Carcinoma; Cell Division; Chemotherapy, Adjuvant; Colorectal Neoplasms; Enzyme Inhibitors; Gefitinib; Humans; Mice; Quinazolines; Radiation-Sensitizing Agents; Transplantation, Heterologous | 2002 |
Cross-resistance to the lipid-soluble antifolate trimetrexate in human carcinoma cells with the multidrug-resistant phenotype.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Line; Drug Resistance; Female; Genes; Humans; Methotrexate; Ovarian Neoplasms; Phenotype; Quinazolines; Quinidine; RNA, Messenger; Trimetrexate; Tumor Cells, Cultured; Verapamil | 1989 |
Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in human lung carcinoma, A549, cells.
Topics: Carcinoma; Cell Survival; Dipyridamole; DNA; Drug Synergism; Folic Acid; Folic Acid Antagonists; Humans; Lung Neoplasms; Quinazolines; Thymidine; Thymidylate Synthase; Tumor Cells, Cultured | 1988 |
Quinazolines. 12. 1,3-Diaminobenzo(f)quinazolines containing long-chain alkyl or chloro substituents on the central ring. Synthesis and biological evaluation as candidate antifolate and antimalarial agents.
Topics: Animals; Antimalarials; Carcinoma; Cell Line; Folic Acid Antagonists; Humans; Lactobacillus; Malaria; Mice; Mouth Neoplasms; Pediococcus; Plasmodium berghei; Quinazolines; Streptococcus; Structure-Activity Relationship | 1974 |